Auto-Injectors Market to Reach US$2.5 bn by 2020

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis.

Request A Sample-
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013.

Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management.

Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others.

The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

View Report-
https://www.transparencymarketresearch.com/global-auto-injectors-market.html

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region.

On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors.

The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.

Request Brochure-
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4199

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website:www.transparencymarketresearch.com

This release was published on openPR.